FINAL PROGRAM - American Society of Gene & Cell Therapy

More documents

Recommendations

Info

13 th AnnUAL MEETing | Washington, DC USA May 19-22, 2010 59Program ScheduleScientific Symposium 31510:30 am - 12:30 pmRoom: Marriott Ballroom Salons 2 & 3Genetic Modification of Stem Cells for Therapeutic ApplicationsChairFrederic D. Bushman, PhDSpeakersChristof von Kalle, MD PhDThe Clonal Distribution of Insertion Site RepertoiresRetroviral vectors have been successfully used for the correction of inherited immune diseases in clinical trials. However, qualitative and quantitative in vivo monitoring ofgene modified hematopoiesis in several clinical gene therapy trials revealed that vector induced side effects, ranging from subtle and not clinically obvious effects to clonaldominance and, rarely, leukemogenesis, have to be considered.Clonality data on oncoretroviral and lentiviral clinical gene therapy trials (i.e. CGD, SCID, WAS, ALD) show that integration site distribution is non-random and mayinfluence cellular gene expression, thus inducing changes in the clonality of the hematopoietic repopulation. Incorporation of next generation sequencing technologiessubstantially improve in depth analyses and monitoring of individual and global clonal contribution in a hitherto unexpected resolution. Prospective monitoring of vectorintegration sites in clinical gene therapy studies is feasible, can detect side effects of gene therapy at the clonal level, and may help to gain new insights into the basicmechanisms leading to specific clonal behaviour in vivo. Genome wide insertion studies will allow to improve the safety and performance of viral and non-viral integratingvector systems.Matthew H. Porteus, MD, PhDGene Targeting with Zinc Finger Nucleases in Primary CellsGene targeting by homologous recombination has the potential to be both a safer and more efficacious approach to gene therapy. Therapeutically relevant rates of genetargeting have been achieved by using zinc finger nucleases in a variety of tissue culture cell lines and some primary human cells. We now demonstrate that therapeuticallyrelevant frequencies of gene targeting by homologous recombination can be achieved in primary cells and that these modified cells can be successfully transplantedback into a recipient. The demonstration that primary cells can be isolated, precisely modified ex vivo and then transplanted back into a recipient mimics the strategy weare working towards in humans as a cure for patients with monogenic diseases.Frederic D. Bushman, PhDHIV DNA Integration: Mechanism and ConsequencesThe lecture will cover integration by HIV and HIV-based vectors. Recent results from gene therapy trials will be presented. The lecture will also cover development ofimproved new methods for integration site isolation and analysis.Ko Mitani, PhDChromosomal Manipulation of Human Pluripotent Stem Cells using Adenoviral VectorsIn order to fully utilize human induced pluripotent stem (iPS) cells and embryonic stem (ES) cells for basic research and clinical applications, it is essential to developefficient methods for homologous recombination (HR) in these cells. We have shown that, by delivering gene-targeting cassettes using helper-dependent adenoviralvectors (HDAdVs) into human ES/iPS cells, gene knock-in/-out has been efficiently achieved at both transcriptionally active and inactive loci. On average, one out of2 - 20 x 105 infected cells was homologous recombinant. The efficiencies of HR per chromosomal integration were 10 - 50% (30 - 90% with negative selection), whichwere ~100-fold higher than those obtained by other DNA delivery methods. These findings suggest that HDAdV-mediated HR is not only a highly efficient strategy forchromosomal manipulation of pluripotent stem cells but also a viable option for ex vivo gene repair therapy using iPS cells derived from patients of inherited diseases,which would overcome the risk of insertional mutagenesis.Friday, May 21 stLunch Break12:30 pm – 2:00 pm
60American Society of Gene & Cell TherapyProgram ScheduleOral Abstract Session 3202:00 pm - 4:00 pmRoom: Marriott Ballroom Salons 2 & 3Clinical Gene & Cell TherapyCo-ChairsGuangping Gao, PhD & Matthew H. Porteus, MD, PhD(Abstracts 289-296; see pages 104-105)Oral Abstract Session 3212:00 pm - 4:00 pmRoom: Virginia SuiteRNA Virus VectorsCo-ChairsFabio Candotti, MD & Robert G. Hawley, PhD(Abstracts 297-304; see page 105)Oral Abstract Session 3222:00 pm - 4:00 pmRoom: Marriott Ballroom Salon 1AAV Vectors: Vector BiologyCo-ChairsDouglas M. McCarty, PhD & Matthew D. Weitzman, PhD(Abstracts 305-312; see pages 105-106)Friday, May 21 stOral Abstract Session 3232:00 pm - 4:00 pmRoom: Delaware SuiteGene Therapy for Lysosomal Storage Diseases and Other Genetic DisordersCo-ChairsCary Harding, MD & Chester B. Whitley, PhD MD(Abstracts 313-320; see page 106)Oral Abstract Session 3242:00 pm - 4:00 pmRoom: Wilson ABCPhysical Methods of DeliveryCo-ChairsJeffrey Hughes, PharmD, PhD & Nancy Smyth Templeton, PhD(Abstracts 321-328; see pages 106-107)EXHIBITOR PROSPECTUSfinal program
Page 1 and 2:
FINAL PROGRAMAmerican Society of Ge
Page 4:
13 th AnnUAL MEETing | Washington,
Page 7 and 8:
6American Society of Gene & Cell Th
Page 12 and 13: 13 th AnnUAL MEETing | Washington,
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 127 and 128:
126American Society of Gene & Cell
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
show all

FINAL PROGRAM - American Society of Gene & Cell Therapy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?